DePuy Synthes, the orthopaedics company of Johnson & Johnson, has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its TELIGEN system, an integrated technology platform that enables minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) procedures through digital tools for visualisation and access.
The TELIGEN system is comprised of a tower that delivers a suite of technologies, including: a camera control system, a VueLIF-T procedure kit with a disposable HD camera, a TELIGEN clear discectomy device and patient-based disposable ports. The TELIGEN system integrates with the UNLEASH bundle of implant solutions, which is designed to streamline the main stages in MIS-TLIF.
Michael Wang, professor of neurosurgery and rehab medicine at the University of Miami Medical Center (Miami, USA), said: “The DePuy Synthes TELIGEN system with VueLIF-T procedure has the potential to change MIS spinal surgery as we know it.
“With the TELIGEN system, we will have a larger and clearer field of view—something we have never had before. This expanded visibility will be invaluable to improving surgical performance and ultimately delivering better patient outcomes.”
Russell Powers, worldwide president, spine, at DePuy Synthes, added: “Improving the MIS spinal surgery experience for both patients and surgeons is a critical step to addressing unmet needs in the industry. With our groundbreaking TELIGEN technology platform, we are providing a better field of view to help improve patient care and increase efficiencies. I’m incredibly proud of this advancement from our DePuy Synthes team and how the VueLIF-T will change MIS spinal procedures.”
DePuy Synthes expects the TELIGEN system to be available later this year in the USA.